Keiji Shiba1
Motohiro Fujiwara1
Ayaka Onuki1Daisuke Kato1Takeshi Shirakawa1Yohei Shimizu1Takumasa Amemiya1Tsunehiro Nenohi1Yuki Matsumoto1
Masayasu Urushibara1Hideto Kano1Kazuhiro Ishizaka1Mikiko Takahashi2
Minato Yokoyama1*- 1Department of Urology, Teikyo University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan
- 2Department of Pathology, Teikyo University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan
Pembrolizumab has emerged as a significant therapeutic option for the treatment of solid tumors with a high tumor mutational burden (TMB-high). However, there have been no reports of its use in treatment-related neuroendocrine prostate carcinoma (t-NEPC) with TMB-high. We present the case of a 66-year-old man with metastatic prostate cancer (adenocarcinoma with a Gleason score of 4 + 5, initial prostate-specific antigen [PSA] level of 267 ng/mL, clinical stage T3bN0M1b) who was initially treated with doublet therapy, including apalutamide and leuprorelin, leading to a reduction in circulating levels of PSA < 0.001 ng/mL. However, 35 months after diagnosis, a retroperitoneal mass developed and neuron-specific enolase (NSE) levels were elevated 62.6 ng/mL. Computed tomography-guided biopsy of the tumor confirmed metastasis of t-NEPC, while genetic profiling revealed a TMB-high status. Pembrolizumab treatment was initiated at the 39-month after diagnosis. At the 41-month after diagnosis, a 75% reduction in the retroperitoneal mass and a decrease in NSE levels to 31 ng/mL were observed. This case suggests that pembrolizumab is a potential treatment option for t-NEPCs with TMB-high.
Introduction
Prostate cancer is the most common malignancy in men worldwide, with > 1.4 million new cases reported in 2020 (1). Androgen pathway inhibition remains the standard of care for patients with metastatic prostate cancer. However, with the progression to castration-resistant prostate cancer (CRPC), the prognosis remains poor despite significant advances in treatment.
One of the major challenges in the treatment of CRPC is the development of treatment-related neuroendocrine prostate carcinoma (t-NEPC). Although most CRPC cases remain dependent on androgen receptor (AR) signaling, approximately 20% of patients eventually lose AR dependence through genetic mutations, amplification, or other mechanisms (2, 3). This leads to a histological transformation into t-NEPC, a more aggressive phenotype characterized by an AR-negative, poorly differentiated small cell morphology. The progression to t-NEPC is associated with resistance to conventional AR-targeted therapies and poor clinical outcomes (2, 4).
In recent years, the development of immune checkpoint inhibitors (ICIs) has expanded the treatment options for various cancers. ICIs enhance antitumor immunity by exposing cancer cells to immune attack. Tumors with a high burden of genetic mutations tend to be more immunogenic because of the expression of abnormal proteins known as neoantigens (5). Thus, ICI therapy has shown efficacy in patients with mismatch repair gene deficiency (dMMR). An international phase 2 trial of pembrolizumab in patients with dMMR cancers demonstrated significant efficacy regardless of tumor origin (6). Additionally, in heavily pretreated patients with unresectable or metastatic solid tumors, a high tumor mutational burden (TMB-high, defined as ≥10 mutations per megabase) was observed to be associated with an improved objective response to pembrolizumab (7). Based on these findings, pembrolizumab was approved by Food and Drug Administration (FDA) for microsatellite instability-high (MSI-H) tumors in 2017, and subsequently for TMB-high solid tumors in 2020 (7). Stemming from our daily clinical practice, we reported a case report of patients with CRPC with MSI-high who were treated with pembrolizumab administration (8).
Despite the growing interest in ICIs for prostate cancer, the occurrence of CRPC with TMB-high status remains rare, occurring in less than 5% of cases, and data on pembrolizumab efficacy in this narrowly defined patient cohort are scarce (9). Moreover, while t-NEPC is well documented, no prior case reports have described pembrolizumab treatment in a patient with t-NEPC and concurrent TMB-high status. Herein, we present the first case of a patient with TMB-high t-NEPC who was treated with pembrolizumab.
Case presentation
A 66-year-old man with no medical history presented with lower back pain. His prostate-specific antigen (PSA) level was elevated at 267 ng/mL. The patient underwent a transperineal prostate biopsy, and the histological findings were adenocarcinoma with a Gleason score of 4 + 5. Computed tomography (CT) and bone scintigraphy demonstrated seminal vesicle invasion and spinal metastasis (Th11-S1), leading to the diagnosis of metastatic castration-sensitive prostate cancer (clinical T3bN0M1b).
Doublet therapy was initiated with apalutamide and leuprorelin, which resulted in a reduction of PSA levels to 0.063 ng/mL at the 9-month after diagnosis. However, owing to taste disturbances, apalutamide was discontinued and the patient was switched to bicalutamide. Subsequently, PSA levels increased to 2.162 ng/mL, and CRPC was diagnosed at the 16-month after diagnosis. A schematic representation of the clinical course of the patient is shown in Figure 1.
Figure 1. Clinical course of the case. CGP, Comprehensive Genomic Profiling; CRPC, Castration-Resistant Prostate Cancer; PSA, Prostate-specific antigen; NSE, Neuron specific enolase; Pem, Pembrolizumab; PRT, Palliative Radiotherapy.
At the 16-month after diagnosis, abiraterone therapy (1000 mg/day) with prednisolone was initiated, and the PSA levels declined to < 0.001 ng/mL. At the 29-month after diagnosis, the patient developed lower back pain; however, chest, abdominal, and pelvic CT scans revealed no new bone metastases or disease progression. At the 35-month after diagnosis, CT scans showed the presence of a retroperitoneal mass and extensive bone metastases (Figure 2A). Magnetic resonance imaging (MRI) revealed progression of lumbar vertebral metastases with lumbar bone marrow infiltration (Figure 2B). Laboratory tests revealed a PSA level of < 0.001 ng/mL and an elevated neuron-specific enolase (NSE) level of 62.6 ng/mL. Then, the patient underwent palliative radiotherapy (30 Gy/10 fractions) for the lumbar spinal metastases. At the 36-month after diagnosis, a CT-guided biopsy of the retroperitoneal mass histologically confirmed the metastasis of t-NEPC (Figure 3). We recommended etoposide and cisplatin therapy; however, the patient refused the treatment. At the 38-month after diagnosis, genomic profiling using FoundationOne® CDx identified TMB-high status and mutations in CDK12, PTEN and STK11. No other genetic mutations, including MSI-high, were detected.
Figure 2. Radiological progression after abiraterone with prednisolone therapy. (A) Pelvic CT showing retroperitoneal mass (arrow heads). (B) T1 weighted MRI revealing progression of lumbar vertebral metastases (arrow heads).
Figure 3. Microscopic appearance: Histological findings of the right retroperitoneal mass at the CT-guided biopsy. (A) Tumor cells with scant cytoplasm were distributed within the hyalinized stroma (arrow heads). Hematoxylin and eosin stain ×100. (B) Tumor cells were immunohistochemically positive for synaptophysin (arrow heads). ×200. (C) Tumor cells were immunohistochemically partial positive for chromogranin A (arrow heads). ×200.
At the 39-month after diagnosis, with PSA levels < 0.001 ng/mL and NSE increasing to 138 ng/mL, pembrolizumab was initiated at a dose of 200 mg every three weeks. At the 41-month after diagnosis, the NSE levels decreased to 31 ng/mL and we observed a 75% reduction (from 130 mm to 33 mm) in the retroperitoneal mass (Figure 4). According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) criteria, this response was classified as a partial response.
Figure 4. CT imaging before and after pembrolizumab administration. (A) CT imaging of retroperitoneal mass before pembrolizumab administration (arrow heads). (B) CT imaging 2 months after pembrolizumab administration. The retroperitoneal mass showed significant shrinkage (arrow heads).
At the 42-month after diagnosis, the NSE levels increased to 77.8 ng/mL, with a new pleural effusion diagnosed as malignant pleuritis by pleural fluid cytology. Pembrolizumab was discontinued at the 43-month after diagnosis due to a further increase in NSE concentration (163 ng/mL) and worsening bilateral pleural effusion. The patient passed away due to cancer progression at the 44-month after diagnosis.
Discussion
In general, t-NEPC occurs in approximately 20% of patients with CRPC (3). The prognosis of t-NEPC cases is often poor and treatment options are limited (3, 10). In a systematic review, the prognosis of t-NEPC cases with multiple metastases was especially poor, and the median overall survival was 7 months (range, 0.5 to 63 months) (11). Conventional prostate cancer markers like PSA may not reflect disease progression in such cases, as demonstrated here (12). Marcus et al. reported that 51.8% of t-NEPC cases progress with PSA levels below 5 (13). Therefore, the follow-up of patients with CRPC should not rely solely on PSA levels, and regular imaging assessments are important.
In terms of the treatment for t-NEPC cases, no prospective studies have been conducted specifically on t-NEPC due to its rarity. Given that the combination of etoposide and cisplatin has proved effective for small cell lung cancer, this regimen has become the most widely used treatment for patients with t-NEPC due to its histological and biological similarities (14, 15). However, data on cisplatin-based chemotherapy for NEPC cases remain limited, with only a few retrospective studies available. Iwamoto et al. reported on platinum-based therapy as a first-line treatment for NEPC, with an objective response rate (ORR) of 66.7% and a median duration of response of 7.5 months (16). Recently, DeLLphi-300 study is underway evaluating the efficacy of tarlatamab as a bispecific T-cell engager (BiTE) that targets DLL3, which is highly expressed in NEPC. In the DeLLphi-300 study, ORR per RECIST v1.1 was 10.5% (95% CI, 2.9-24.8) (17). To date, no clearly defined standard treatment for t-NEPC has been established, highlighting the need for individualized therapeutic approaches (18).
Regarding TMB-high status case occurrence, the KEYNOTE-158 trial revealed that 29.3% of all neuroendocrine cancers, including prostate cancer, have a TMB-high status (19). In prostate cancer, a TMB-high status is rare in hormone-naïve prostate cancer (< 5%) and is more commonly observed in patients who have received hormone therapy for over 24 months (20). Similar to t-NEPC, no prospective studies have been conducted specifically on prostate cancer with a TMB-high status due to its rarity. The KEYNOTE-158 trial demonstrated the efficacy of pembrolizumab in treating TMB-high solid tumors, suggesting that the TMB-high status is a predictive biomarker of treatment response in a variety of cancers, including prostate cancer (7, 20, 21). The KEYNOTE-158 trial reported a higher ORR in TMB-high tumors compared to TMB-low tumors, regardless of PD-L1 expression or tumor type (21). TMB-high has many genetic mutations that allow more neo-antigens to be presented to T cells through the major histocompatibility complex (MHC) molecules. Pembrolizumab blocks programmed cell death 1 receptors and stimulates T cell activation, so the presence of TMB-high allows more neoantigens to be presented to T cells through the MHC molecules, increasing the effectiveness of pembrolizumab (5). The loss of efficacy of pembrolizumab is due to decreased expression of MHC molecules on tumor cells, as well as an increased immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells. These changes impair the ability of T cells to recognize and attack tumor cells. In prostate cancer, which is often characterized as a “cold tumor” with inherently low T cells and an immunosuppressive microenvironment. Even if pembrolizumab had an initial effect, as in this case, the tumor’s immune evasion mechanism may have been further enhanced, resulting in the development of resistance to pembrolizumab (22). In the patient, this feature would have resulted in a short-term response to pembrolizumab.
In addition to the TMB-high status, an MSI-high condition has also been recognized as a biomarker for predicting the efficacy of ICIs, including pembrolizumab. Notably, 82.1% of MSI-high status tumors are also TMB-high, whereas only 18.3% of TMB-high tumors exhibit an MSI-high status (23). While pembrolizumab demonstrated an ORR of 34.3% in MSI-high status tumors, the ORR for TMB-high status tumors was 29% (7, 24). Importantly, pembrolizumab is also considered an effective treatment option for TMB-high status tumors that do not display an MSI-high condition, as in the patient described here (21). However, Mosalem et al. have reported that only one in six patients with a TMB-high status and without an MSI-high condition responded to pembrolizumab (25). Further accumulation of cases and clinical evidence are needed to clarify the therapeutic role of pembrolizumab in this patient cohort.
This report is particularly noteworthy because it described the first case of pembrolizumab treatment for a patient with CRPC with both t-NEPC and TMB-high status. The rapid tumor response observed in this case suggested that pembrolizumab may be a potential treatment for this rare subset of patients with prostate cancer. Additionally, this case highlighted the importance of genomic profiling in patients with CRPC. Although the occurrence of a TMB-high status is rare in patients with prostate cancer, its identification through genome profiling may help guide treatment decisions and enable us to use pembrolizumab in selected cases.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Ethics statement
Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and the institutional requirements. Written informed consent was obtained from the patient for the publication of this case report.
Author contributions
KS: Writing – original draft, Writing – review & editing. MF: Writing – original draft, Writing – review & editing. AO: Writing – review & editing. DK: Writing – review & editing. TS: Writing – review & editing. YS: Writing – review & editing. TA: Writing – review & editing. TN: Writing – review & editing. YM: Writing – review & editing. MU: Writing – review & editing. HK: Writing – review & editing. KI: Writing – review & editing. MT: Writing – review & editing, Writing – original draft. MY: Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Wang L, Lu B, He M, Wang Y, Wang Z, and Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. (2022) 10:1–10. doi: 10.3389/fpubh.2022.811044, PMID: 35252092
2. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. (2016) 22:298–305. doi: 10.1038/nm.4045, PMID: 26855148
3. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J Clin Oncol. (2018) 36:2492–503. doi: 10.1200/JCO.2017.77.6880, PMID: 29985747
4. Beltran H and Demichelis F. Therapy considerations in neuroendocrine prostate cancer: what next? Endocr Relat Cancer. (2021) 28:67–78. doi: 10.1530/ERC-21-0140, PMID: 34111024
5. Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, and Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. (2020) 10:1808–25. doi: 10.1158/2159-8290.CD-20-0522, PMID: 33139244
6. Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. (2022) 33:929–38. doi: 10.1016/j.annonc.2022.05.519, PMID: 35680043
7. Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. (2021) 27:4685–9. doi: 10.1158/1078-0432.CCR-21-0327, PMID: 34083238
8. Fujiwara M, Komai Y, Yuasa T, Numao N, Yamamoto S, Fukui I, et al. Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high. IJU Case Rep. (2020) 3:62–4. doi: 10.1002/iju5.12144, PMID: 32743472
9. Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann Oncol. (2019) 30:44–56. Oxford University Press. doi: 10.1093/annonc/mdy495, PMID: 30395155
10. Cacciatore A, Albino D, Catapano CV, and Carbone GM. Preclinical models of neuroendocrine prostate cancer. Curr Protoc John Wiley Sons Inc. (2023) 3:e742. doi: 10.1002/cpz1.742, PMID: 37166213
11. Wang HT, Yao YH, Li BG, Tang Y, Chang JW, and Zhang J. Neuroendocrine Prostate Cancer (NEPC) Progressing from conventional prostatic adenocarcinoma: Factors associated with time to development of nepc and survival from NEPC Diagnosis-A systematic review and pooled analysis. J Clin Oncol. (2014) 32:3383–90. doi: 10.1200/JCO.2013.54.3553, PMID: 25225419
12. Lee DK, Park JH, Kim JH, Lee SJ, Jo MK, Gil MC, et al. Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J Urol. (2010) 51:358–61. doi: 10.4111/kju.2010.51.5.358, PMID: 20495701
13. Marcus DM, Goodman M, Jani AB, Osunkoya AO, and Rossi PJ. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis. (2012) 15:283–8. doi: 10.1038/pcan.2012.4, PMID: 22349984
14. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, and Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. (1992) 147:935–7. doi: 10.1016/S0022-5347(17)37427-X, PMID: 1311396
15. Suzuki K, Terakawa T, Jimbo N, Inaba R, Nakano Y, and Fujisawa M. Clinical features of treatment-related neuroendocrine prostate cancer: A case series. Anticancer Res. (2020) 40:3519–26. doi: 10.21873/anticanres.14340, PMID: 32487653
16. Iwamoto H, Nakagawa R, Makino T, Kadomoto S, Yaegashi H, Nohara T, et al. Treatment outcomes in neuroendocrine prostate cancer. Anticancer Res. (2022) 42:2167–76. doi: 10.21873/anticanres.15699, PMID: 35347041
17. Aggarwal RR, Rottey S, Bernard-Tessier A, Na Mellado-Gonzalez B, Kosaka T, Stadler WM, et al. Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). J Clin Oncol. (2024) 42:5012. doi: 10.1200/JCO.2024.42.16_suppl.5012
18. Ishizaki M, Hasumi M, Muramatsu K, and Shimizu N. Prostate neuroendocrine carcinoma successfully treated with etoposide and cisplatin. IJU Case Rep. (2024) 7:491. doi: 10.1002/iju5.12787, PMID: 39498181
19. Shao C, Li G, Huang L, Pruitt S, Castellanos E, Frampton G, et al. Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw Open. (2020) 3:e2025109. doi: 10.1001/jamanetworkopen.2020.25109, PMID: 33119110
20. Hougen HY, Graf RP, Li G, Quintanilha JCF, Lin DI, Ross JS, et al. Clinical and genomic factors associated with greater tumor mutational burden in prostate cancer. Eur Urol Open Sci. (2023) 55:45–9. doi: 10.1016/j.euros.2023.08.001, PMID: 37662703
21. Cristescu R, Aurora-Garg D, Albright A, Xu L, Liu XQ, Loboda A, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: A pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. (2022) 10:e003091. doi: 10.1136/jitc-2021-003091, PMID: 35101941
22. Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. (2023) 14:663. doi: 10.1038/s41467-023-36325-2, PMID: 36750562
23. Goodman AM, Sokol ES, Frampton GM, Lippman SM, and Kurzrock R. Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res. (2019) 7:1570–3. doi: 10.1158/2326-6066.CIR-19-0149, PMID: 31405947
24. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, de Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. (2020) 38:1–10. doi: 10.1200/JCO.19.02105, PMID: 31682550
25. Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, et al. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis. Prostate Cancer Prostatic Dis. (2025) 28:138–44. doi: 10.1038/s41391-024-00799-y, PMID: 38341460
Keywords: pembrolizumab, prostate cancer, tumor mutational burden, treatment-related neuroendocrine prostate carcinoma, immune checkpoint inhibitors
Citation: Shiba K, Fujiwara M, Onuki A, Kato D, Shirakawa T, Shimizu Y, Amemiya T, Nenohi T, Matsumoto Y, Urushibara M, Kano H, Ishizaka K, Takahashi M and Yokoyama M (2025) Pembrolizumab for treatment-related neuroendocrine prostate carcinoma with a high tumor mutational burden: a case report. Front. Oncol. 15:1642412. doi: 10.3389/fonc.2025.1642412
Received: 06 June 2025; Accepted: 15 July 2025;
Published: 01 August 2025.
Edited by:
Megan Ludwig, University of Minnesota Twin Cities, United StatesReviewed by:
Pengfei Xu, University of California, Davis, United StatesNicholas Zorko, University of Minnesota Twin Cities, United States
Copyright © 2025 Shiba, Fujiwara, Onuki, Kato, Shirakawa, Shimizu, Amemiya, Nenohi, Matsumoto, Urushibara, Kano, Ishizaka, Takahashi and Yokoyama. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Minato Yokoyama, eW9rb3lhbWEubWluYXRvLmp3QHRlaWt5by11LmFjLmpw